Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 3,571 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: T cells Clear all

Conditions: Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions: Nemtabrutinib, Brexucabtagene autoleucel ( other names: brexu-cel , Tecartus); Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Adult Liposarcoma, Adult Synovial Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
Interventions: cyclophosphamide, NY-ESO-1-specific T cells, laboratory biomarker analysis; Drug · Biological · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Prostate Cancer, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma
Interventions: Ipilimumab, Nivolumab, Enzalutamide; Biological · Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Psoriasis
Interventions: Imiquimod, Clobetasol; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Kidney Cancer
Interventions: dactinomycin, filgrastim, cyclophosphamide, doxorubicin hydrochloride, etoposide, vincristine sulfate, conventional surgery, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 0 Years to 15 Years
Enrollment: 3,031 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2003
U.S. locations: 206
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more

Conditions: Multiple Myeloma
Interventions: myPRS, Induction 1 - MEL-10+CFZ-TD-PACE, First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Inter-Therapy - MEL-20+CFZ-TD-PACE (75%), Second Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Consolidation - CFZ-TD-PACE, Maintenance - CFZ-R(T)-D; Device · Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions: Aldesleukin, Antibody Therapy, Fluorouracil, Gemcitabine Hydrochloride, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Oxaliplatin, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Sargramostim; Biological · Drug · Other
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Non-small Cell Lung Cancer, Melanoma
Interventions: IMM60, Pembrolizumab; Drug
Lead sponsor: iOx Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 5
States / cities: Los Angeles, California • Boston, Massachusetts • Detroit, Michigan + 2 more

Conditions: Hematologic Diseases
Interventions: Allogeneic Stem Cell Transplant, CliniMACS Prodigy System, T-allo10 cells addback; Biological · Device · Drug
Lead sponsor: Porteus, Matthew, MD; Other
Eligibility: 1 Month to 45 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD), EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma
Interventions: Tabelecleucel; Biological
Lead sponsor: Pierre Fabre Medicament; Industry
Eligibility: Not listed
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 23
States / cities: Los Angeles, California • Orange, California • Palo Alto, California + 18 more

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions: ravuconazole; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV-1-infection
Interventions: ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3, MVA.tHIVconsv4, Vesatolimod (VES), GS-5423, GS-2872, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 9
States / cities: San Diego, California • Atlanta, Georgia • Chicago, Illinois + 6 more

Conditions: B-All, Acute Lymphoblastic Leukemia
Interventions: TSLPR-CART, Cyclophosphamide, Fludarabine; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Scleroderma, Systemic
Interventions: Thalidomide, Placebo thalidomide; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Leukemia, Acute, Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Interventions: Regulatory T-cells, Conventional T-cells, Melphalan, Thiotepa, Fludarabine, Anti-thymocyte globulin, rabbit, CliniMACS CD34 Reagent System; Drug · Device
Lead sponsor: Everett Meyer; Other
Eligibility: Up to 60 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Stanford, California

Conditions: Hidradenitis Suppurativa
Interventions: SBT777101; Biological
Lead sponsor: Sonoma Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Boston, Massachusetts • Minneapolis, Minnesota • St Louis, Missouri + 3 more

Conditions: Ewing's Sarcoma, Rhabdomyosarcoma
Interventions: EF-1 Peptide, EF-2 Peptide, PXFK Peptide, E7 Peptide, IL-2, IL-4, GM-CSF, CD40 Ligand; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 30 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Mycosis Fungoides
Interventions: Valchlor; Drug
Lead sponsor: Helsinn Therapeutics (U.S.), Inc; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 36
States / cities: Little Rock, Arkansas • Duarte, California • La Mesa, California + 28 more

Conditions: Ebola Hemorrhagic Fever, Ebola Virus Disease, Ebola Virus Vaccines, Envelope Glycoprotein, Ebola Virus, Filovirus
Interventions: VRC-EBOADV018-00-VP; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Bladder Cancer
Interventions: Fluorine F 18 Ara-G, Positron Emission Tomography, Magnetic Resonance Imaging; Drug · Procedure
Lead sponsor: Lawrence Fong; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Lung Carcinoma, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma, Metastatic Lung Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Electronic Health Record Review; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Neoplasms
Interventions: letetresgene autoleucel (GSK3377794), Cyclophosphamide, Fludarabine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 6
States / cities: Tampa, Florida • Ann Arbor, Michigan • St Louis, Missouri + 3 more

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions: Busulfan, Cyclophosphamide; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 6 Months to 65 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions: AUTO3; Biological
Lead sponsor: Autolus Limited; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 7
States / cities: Duarte, California • Denver, Colorado • Miami, Florida + 4 more

Search by objective public record fields.

Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma

Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery

Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7

Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis

Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer

UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer

IMM60 and Pembrolizumab in Melanoma and NSCLC

Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback

A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation

Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis

Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells

Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa

A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas

Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma

Experimental Vaccine for Prevention of Ebola Virus Infection

Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1

Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types

Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma

Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer

Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma